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Abstract
Background: Acute respiratory infections (ARIs) are common in outpatient practice, and the severity of symptoms
contributes to the overall burden of illness. We examined the association between a subjective symptom severity
score, demographic and clinical characteristics, and presence of laboratory-confirmed influenza among central Wisconsin
adults who sought care for ARI during four influenza seasons. We hypothesized that adults with laboratory-confirmed
influenza would rate their symptoms as more severe relative to adults without influenza, and vaccinated adults
with influenza would rate symptoms as less severe than those who were not vaccinated.
Methods: Patients with acute respiratory illness, including feverishness or cough symptoms ≤ 7 days duration,
were prospectively enrolled and tested for influenza by reverse transcription polymerase chain reaction (RT-PCR)
during influenza seasons 2007–08 through 2010–11. Perceived severity was self-rated during the enrollment
interview for eight symptoms, on a scale of 0 (absent) to 3 (severe). Scores for each symptom were summed to
generate a combined severity score ranging from 1 to 24 for each individual. The association between influenza
test result and severity score was examined using linear regression.
Results: There were 2,374 individuals included in the analysis, including 324 with RT-PCR confirmed influenza.
The mean symptom severity score was 12.3 (±4.1) points, and the most common symptoms were cough (92%),
fatigue (91%), and nasal congestion (84%). In the final adjusted model, influenza infection was the strongest independent
predictor of higher severity score, with a mean increase of 1.7 points compared to those who were influenza negative
(p < 0.001). Among adults with influenza, the association between influenza vaccination and symptom severity
was modified by age (p < 0.001). In adults ≥ 65 years old with RT-PCR confirmed influenza, symptom severity
was 31% lower in those who were vaccinated as compared to those who were not vaccinated.
Conclusions: Influenza is associated with more severe symptoms of acute respiratory illness. The association
between influenza vaccination and reduced symptom severity in older adults should be confirmed and
explored further in other populations and seasons.
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Background
Acute respiratory infections (ARIs) collectively represent
the most common seasonal illness, affecting adults three
times annually on average [1,2]. Most ARIs are caused
by viruses, including influenza [2]. Studies addressing
the burden of illness from viral ARI have historically fo-
cused on high-risk populations [3-7] and severe outcomes
such as emergency room visits [8], hospitalizations [9-12],
and death [13,14]. However, the severity of ARI symptoms
in individuals seeking and receiving outpatient care also
contributes to the overall illness burden [15]. Such indi-
viduals may not experience severe health complications,
but their illnesses nevertheless account for a significant
economic burden in lost workplace productivity [16]. Be-
cause symptom severity is often a determining factor in
seeking healthcare for ARI, it underlies billions of dollars
in direct medical care expenditures in the United States
[17]. Many large observational studies on ARI and
influenza-like illness focus on individuals seeking ambula-
tory medical care, thus a better understanding of the se-
verity of ARI symptoms may improve the interpretability
of results of such studies.
From both an economic and public health perspective,
influenza is one of the most important viruses because it
may cause more severe symptoms than other respiratory
viruses. The severity of seasonal influenza symptoms
compared to non-influenza ARI has not been extensively
studied though. One study reported an association be-
tween increased symptom severity in patients with la-
boratory confirmed 2009 pandemic influenza compared
to seasonal influenza [18]; limited evidence also suggests
that influenza ARI may be more severe than ARI due to
other causes [19]. In an influenza challenge study, symp-
tom severity was associated with increased magnitude of
influenza virus shedding [20]. Given its role in generat-
ing an immune response and the production of anti-
bodies, influenza vaccination may mitigate the severity
of some influenza symptoms. Evidence of this hypothe-
sized impact is incomplete, however, with one study of
hospitalized influenza cases demonstrating fewer deaths
and ICU admissions (used as markers of severe clinical
complications) among those who received a seasonal in-
fluenza vaccination [21].
It is well established that ARIs, including influenza, do
not affect all patients uniformly [22], yet little is known
about host factors and virulence characteristics that are
associated with specific ARI symptoms. We had the op-
portunity to examine the severity of symptoms, along
with demographic and clinical features, in adults pre-
senting to an outpatient facility with ARI. Because influ-
enza may present with more severe features relative to
ARI of other etiologies, we hypothesized that symptom
severity would be rated higher among adults with RT-
PCR confirmed influenza. A secondary hypothesis was
that influenza vaccination was associated with reduced




A cross-sectional analysis was employed using data from
annual studies of influenza vaccine effectiveness (VE)
among community-dwelling residents of a 14 zip code
area surrounding Marshfield, Wisconsin. The VE study
methods are described in more detail in previous publi-
cations [23]. Briefly, patients in this population were
screened and enrolled by trained research coordinators
during or directly after an encounter for acute respira-
tory illness with symptoms of fever or cough. During the
2007–08 season, patients reporting chills were also eli-
gible for enrollment. Potential participants with illness
duration >7 days were excluded to minimize false nega-
tive influenza test results. Research coordinators used an
electronic appointment system to screen for chief com-
plaints and identify potential participants in primary care
departments at the Marshfield Clinic main campus. Eli-
gible patients were also recruited from the Emergency
Department and an adjacent hospital; individuals en-
rolled at hospital admission were excluded from this
analysis. Patients who could not be approached during
their clinical encounter were contacted by phone on the
following day if they received an International Classifica-
tion of Disease (Version 9) (ICD-9) diagnosis code indi-
cating acute respiratory illness. Those who met eligibility
criteria were invited to participate.
Each adult participant was interviewed at the time of
enrollment to determine illness onset date, and the pres-
ence and severity of symptoms. Nasopharyngeal swabs
or combined nasal and oropharyngeal swabs were also
obtained as part of the enrollment interview and tested
for influenza by reverse transcription polymerase chain
reaction (RT-PCR). Nucleic acid was extracted from
samples using the Roche MagNA Pure Total Nucleic
Acid Kit (Roche Diagnostics, Indianapolis, Indiana), and
RT-PCR was performed using the LightCycler® Real-
Time PCR System (Roche Diagnostics, Basel, Switzerland).
The U.S. Centers for Disease Control and Prevention In-
fluenza Division provided sequence information for RT-
PCR primers and probes. The TaqMan®-based RT-PCR
assay detects two highly-conserved influenza genes: the
matrix gene of influenza A and the non-structural gene of
influenza B. A human RNase P gene served as a positive
control for human nucleic acid. For a subset of study par-
ticipants with RT-PCR confirmed influenza, cycle thresh-
old (Ct) values were analyzed. Ct values describe the
number of times that DNA must be replicated in a par-
ticular sample in order to reach a level detectable by a
PCR system. Ct values have therefore been used as a
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surrogate marker of viral titers. For a given respiratory
sample, a lower Ct value indicates a greater amount of
viral material present [24,25].
The recruitment period generally corresponded to periods
of influenza transmission from 2007–08 to 2010–11. The
length of enrollment ranged from 10 weeks in 2007–08 to
26 weeks in 2009–10 (December to May). For this analysis,
we excluded enrollments occurring during the 2009 pan-
demic wave (October-November), since the clinical features
and symptom severity scores have been previously reported
[18]. The VE study procedures were approved by the Marsh-
field Clinic Institutional Review Board and informed consent
was obtained from all participants.
Symptom severity score
The primary outcome for this analysis was ARI symp-
tom severity score, which was assessed at (and reflected
symptom severity at) the time of the enrollment inter-
view and before any RT-PCR results were disclosed.
Symptom severity score was assessed using a subjective
self-rating of eight symptoms, including two upper re-
spiratory (nasal congestion, sore throat), two lower re-
spiratory (cough, wheezing), and four systemic symptoms
(feverishness, fatigue, headache, muscle aches). Partici-
pants rated each of their symptoms on an ordinal scale
that included response options of absent (0), mild (1),
moderate (2), or severe (3). These symptom ratings were
summed to create a symptom severity score with a pos-
sible range of 1–24 points, where higher scores indicated
greater perceived severity of symptoms. All participants
had a minimum score of 1 because either feverishness or
cough was required for enrollment in all seasons.
Predictor variables
The primary predictor variables were influenza RT-PCR
result and age. Based on previously observed associa-
tions with RT-PCR confirmed influenza in some seasons,
other considered exposures included sex, type of health
insurance, enrollment season, days between symptom
onset and enrollment, number of outpatient visits in the
past five years, same-season influenza vaccination status,
blood pressure (high [≥140/90 mmHg], borderline [120-
139/80-89 mmHg], normal [<120/80 mmHg]), total chol-
esterol (high [≥240 mg/dL], borderline [200–239 mg/dL],
normal [<200 mg/dL]), body mass index (BMI) (obese
[≥30 kg/m2], overweight [25–29 kg/m2], normal [<25 kg/
m2]), smoking history (current, former, never), and per-
sonal history of chronic pulmonary disease, diabetes, and/
or cardiovascular disease (CVD). Chronic disease status
was determined by the presence of specific ICD-9 diag-
nostic codes in the electronic health record (list of codes
available on request). For BMI, blood pressure, and chol-
esterol, the most recent recorded value within five years
prior to VE study enrollment date was used. BMI was
calculated as weight in kilograms divided by height in
meters squared. Influenza vaccination status (including
vaccination date) was ascertained from an online
immunization registry that is linked to clinical and
non-clinical vaccination records from the region. This
registry has been demonstrated to capture over 95% of in-
fluenza vaccines administered in this study population [26].
Analyses
Linear regression was performed to examine the associa-
tions between symptom severity score, influenza, age,
and other covariates. Data from all seasons were com-
bined and symptom severity score was modeled as a
continuous variable since it was normally distributed.
Collinearity between exposure variables was assessed by
examining the variance inflation factors and condition
index statistics [27]. No collinearity issues were discov-
ered; therefore univariate models were first created to
assess the crude association between each exposure and
symptom severity score. A fully adjusted multivariable
model was then fit with all exposures and all possible
two- and three-way interaction terms between influenza,
age, sex, and vaccination status. Along with influenza
and age, exposures with a significant (p < 0.05) associ-
ation in the univariate models were considered for in-
clusion in the final, reduced multivariable model. All
considered exposure terms were initially entered simultan-
eously and manual, backward selection criteria were applied
to sequentially eliminate exposures that were not independ-
ently associated with symptom severity score. Secondary
analyses of Ct values in participants with RT-PCR confirmed
influenza included non-parametric t-tests to examine Ct dif-
ferences by vaccination status. Analytical procedures were
conducted using SAS Version 9.3 (Cary, NC).
Results
There were 2,374 participants who met all eligibility cri-
teria and were included in the analysis. Two-thirds of
participants were female, and the majority was under
age 50 years (55%), with 29% and 16% in the 50–64 years
and ≥65 years groups, respectively (Table 1). Mean
(±SD) symptom severity score was 12.3 (±4.1) points
overall, with significantly decreased symptom severity in
older age groups (p < 0.001). Influenza was significantly
less common in older age groups (p = 0.012), with rates
of RT-PCR confirmed influenza being 15%, 13%, and 9%
in participants age 18–49, 50–64, and ≥65 years, respect-
ively. The most common symptoms were cough (93%),
fatigue (91%), nasal congestion (84%), headache (76%),
sore throat (76%), muscle aches (70%), fever (69%), and
wheezing (49%). The median severity rating for each
symptom, when present, was ‘moderate.’ In unadjusted
univariate models, higher symptom severity score was
significantly associated with younger age group, female
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Table 1 Descriptive characteristics of study participants with acute respiratory illness during four influenza seasons
Characteristic N (%) Mean ± SD symptom severity score P-value1
Age (years)
18-49 1299 (54.7) 12.7 ± 4.1 < 0.0001
50-64 676 (28.5) 12.3 ± 4.0
≥ 65 399 (16.8) 10.8 ± 4.2
Gender (female) 1591 (67.0) 12.6 ± 4.1 < 0.0001
Health insurance
Private only 1200 (50.6) 12.2 ± 3.8 0.56
Public-assisted 1082 (45.6) 12.4 ± 4.4
vNone 92 (3.9) 12.2 ± 4.5
Study season
2007-08 249 (10.5) 13.0 ± 4.1 0.006
2008-09 672 (28.3) 12.4 ± 4.4
2009-10 838 (35.3) 12.0 ± 4.0
2010-11 615 (25.9) 12.2 ± 4.0
Days elapsed between symptom onset and date of enrollment
0 67 (2.8) 10.0 ± 4.1 < 0.0001
1-2 654 (27.6) 12.3 ± 4.0
3-4 798 (33.6) 12.5 ± 4.1
5-6 534 (22.5) 12.2 ± 4.1
≥ 7 321 (13.5) 12.1 ± 4.2
Number of ambulatory care visits within the past 5 years
0-20 334 (17.4) 11.6 ± 4.0 0.009
21-40 603 (31.4) 12.0 ± 4.0
41-60 474 (24.7) 12.4 ± 4.1
61-80 313 (16.3) 12.4 ± 4.3
81-100 195 (10.2) 12.7 ± 4.1
≥ 101
Influenza infection 324 (13.7) 13.9 ± 3.9 < 0.0001
Presence of chronic disease
Pulmonary disease 296 (12.5) 12.4 ± 4.2 0.43
Diabetes 290 (12.2) 12.1 ± 4.2 0.43
Cardiovascular disease 322 (13.6) 11.8 ± 4.4 0.05
Blood pressure (systolic/diastolic mmHg)
< 120/80 (healthy) 724 (30.5) 12.3 ± 3.9 0.59
120-139/80–89 (borderline) 1159 (48.8) 12.3 ± 4.2
≥ 140/90 (high) 491 (20.7) 12.1 ± 4.3
Total cholesterol (mg/dL)
< 200 (healthy) 1644 (69.3) 12.1 ± 4.1 0.002
200-239 (borderline) 566 (23.8) 12.7 ± 4.2
≥ 240 (high) 164 (6.9) 12.7 ± 4.1
Body mass index (kg/m2)
< 25 (healthy) 465 (19.6) 12.3 ± 3.9 0.01
25-29 (overweight) 648 (27.3) 12.3 ± 4.2
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gender, a greater number of recent ambulatory visits,
not being vaccinated for influenza, borderline high chol-
esterol, higher BMI, and current smoking (see Table 1).
Influenza varied significantly by enrollment season and
time interval between symptom onset and enrollment.
Compared to those with symptom severity scores below
the median, more participants tested positive for influ-
enza among those with symptom severity scores above
the median (Figure 1).
The main findings from the final adjusted model in
Table 2 indicated that female gender, more ambulatory
care visits, borderline high cholesterol, obesity, and
smoking (both current and former) were associated with
significantly higher symptom severity scores. In addition,
there was a significant three-way interaction observed
between age group, influenza, and vaccination status.
Age modified the association between vaccination status
and symptom severity in patients who were influenza
positive (Figure 2). Mean symptom severity generally de-
clined with increasing age, but remained highest among
non-vaccinated individuals with influenza. Among par-
ticipants ≥65 years old with influenza, mean symptom
severity scores were 5–6 points higher in those who
were not vaccinated relative to those who were vaccinated
or those who did not have influenza (regardless of vaccin-
ation status; p <0.001 for all pairwise comparisons).
Table 1 Descriptive characteristics of study participants with acute respiratory illness during four influenza seasons
(Continued)
≥ 30 (obese) 1261 (53.1) 12.1 ± 4.3
Smoking status
Never 1259 (53.0) 11.9 ± 3.9 < 0.0001
Former 719 (30.3) 12.5 ± 4.3
Current 396 (16.7) 12.9 ± 4.4
1P-value corresponds to t-test comparing symptom severity score between each characteristic category.
Figure 1 Number of participants who were influenza positive and negative by symptom severity score. The percentages above each bar
correspond to the percent of participants who were influenza positive at each symptom severity score value.
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Significant reductions in the severity of cough and fe-
verishness, as well as a decreased presence of wheez-
ing, largely explained the lower symptom severity
scores observed in the older, vaccinated group with in-
fluenza (Table 3).
In a secondary analysis, Ct values were examined from
RT-PCR confirmed influenza positive samples. Due to
the relatively small available sample for this analysis, Ct
values were dichotomized as having a high or low viral
load based on the median value of 25.7. Among all influ-
enza positive participants, the median severity score was
15 for those with a high viral load and 13 for those with a
low viral load (p = 0.09). Among adults ≥ 65 years old, the
median severity score was 12 for those with a high viral
load and 12 for those with a low viral load (p = 0.27).
There was no association between vaccination status and
Table 2 Multivariable associations between participant demographic and clinical characteristics and symptom severity
(N = 2,374)1
Characteristic Difference in average adjusted
symptom severity score2
Standard error P-value
Age (years) (ref.: 18–49)
50-64 −0.19 0.35 0.51
≥ 65 −3.08 0.49 < 0.0001
Female gender 0.99 0.18 < 0.0001
Days elapsed between symptom onset and enrollment date (ref.: ≥ 7)
5-6 0.06 0.28 0.82
3-4 0.04 0.26 0.87
1-2 −0.27 0.27 0.31
0 −2.45 0.53 < 0.0001
Number of ambulatory care visits in the past five years 0.01 0.001 < 0.0001
Influenza infection3 1.73 0.36 < 0.0001
Vaccinated against influenza −0.39 0.24 0.11
Total cholesterol (mg/dL) (ref.: < 200)
200-239 0.67 0.19 0.0006
≥ 240 0.46 0.32 0.15
Body mass index (kg/m2) (ref.: < 25)
25-29 0.27 0.24 0.27
≥ 30 0.61 0.22 0.005
Smoking (ref.: Never)
Current 0.63 0.23 0.006
Former 0.73 0.19 < 0.0001
Interaction: Age x influenza
50-64 × influenza infection 0.23 0.72 0.75
≥ 65 × influenza infection 4.21 1.37 0.002
Interaction: Age × influenza vaccination
50-64 × vaccinated −0.48 0.41 0.24
≥ 65 × vaccinated 1.45 0.57 0.01
Interaction: Influenza infection x influenza vaccination 0.92 0.68 0.17
Interaction: Age x influenza infection x influenza vaccination
50-64 x influenza infection × vaccinated −1.02 1.11 0.36
≥ 65 × influenza infection × vaccinated −6.75 1.68 < 0.0001
1Bolded values denote point estimate was significant (p < 0.05). Significant exposures in the crude models were also considered for inclusion in the final
reduced model.
2Values are reported as point estimate ± standard error, p-value. Positive values with p < 0.05 indicate a significantly greater symptom severity score relative to the
reference category (or 1-unit increase for continuous predictors) and negative values with p < 0.05 indicate a significantly lower symptom severity score relative to
the reference category.
3Influenza infection refers to infection with either influenza A or B.
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viral load among all participants with influenza (p = 0.62).
Among vaccinated adults ≥65 years old, the median sever-
ity score was 12 and 10, respectively, for those with a high
and low viral load (p = 0.32).
Discussion
Symptom severity can serve as a useful and complemen-
tary measure of respiratory disease impact among individ-
uals seeking care for respiratory illness in the outpatient
setting. Perceived ARI symptom severity was greatest in
younger adults, women, and individuals with RT-PCR
confirmed influenza in this study. As expected, influenza
infection was most closely associated with increased
symptom severity. The presence of diagnosed CVD, pul-
monary disease, or diabetes had little association with
symptom severity, though some disease risk factors
(e.g., obesity, smoking, dyslipidemia) were modestly
associated with higher symptom severity scores.
The subgroup analysis of influenza positive partici-
pants identified an association between influenza vaccin-
ation and reduced symptom severity in older age groups.
Compared to ≥ 65 year old adults who were influenza
positive but not vaccinated, perceived symptom severity
was 31%-39% lower in older adults who were influenza
negative or who were vaccinated. This difference was
primarily driven by reductions in the severity of cough
and feverishness, as well as reduced presence of wheez-
ing, in those who received the vaccine. However, there
were only 10 unvaccinated individuals with influenza
who were ≥ 65 years old; therefore these findings could
reflect random variation as a function of the small sam-
ple size. The biological basis for reduced symptom sever-
ity in vaccinated older adults (but not in younger adults)
is unclear and largely speculative at this point. The
humoral and cell-mediated immune response to natural
influenza infection and influenza vaccination declines
with increased age, thus the potential vaccine benefits in
terms of symptom mitigation would seem to be more
likely in younger, rather than older, individuals [28,29]. It
is also possible that the observed reductions in systemic
(fever) and lower respiratory (wheezing) symptoms could
have resulted from reduced influenza virus replication in
vaccinated versus unvaccinated older adults. However,
our analysis of RT-PCR Ct values as a surrogate measure
of viral load did not reveal any significant associations
with either severity score or vaccination status. There
may also be perceptual reasons that explain why those
in older age groups or who received a prior influenza
Figure 2 Least-squares adjusted symptom severity scores, stratified by age group, influenza, and vaccination status (N = 2,374).
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vaccination perceived their symptoms differently. Fur-
ther research is needed to understand the relationship
between vaccination, influenza severity, and virus shed-
ding in older adults.
Strengths of this study included recruitment from a
defined population cohort over multiple seasons, sys-
tematic screening and enrollment, standardized report-
ing of severity at the time of enrollment, use of a
validated immunization registry, and confirmation of in-
fluenza using a highly sensitive and specific RT-PCR test.
From a limitations perspective, individuals who did not
receive medical attention for their ARI were not re-
cruited, thus results are not necessarily generalizable to
all influenza illness cases in the community. From a
measurement perspective, variations of the ARI symp-
tom severity metric used in this study have been used in
numerous other investigations [30-38] and have been
previously correlated with influenza positive status [19]
and viral shedding [20], but have not been formally vali-
dated and remain a subjective measure of symptom
perceptions that may be subject to recall and self-
presentation biases, as is common with some other
self-reported metrics [39]. This is a particular concern
in some subgroup comparisons where symptom sever-
ity expectations may vary as a result of perceptual
priming during study enrollment (e.g., different beliefs
on how influenza vaccination should impact symp-
toms). Additional research is also needed in this area
to better understand self-reported ARI symptom sever-
ity and its relationship to functional disability and ser-
ious medical complications. In addition to influenza,
future studies should also examine symptom severity
for other specific pathogens and virus infections such
as RSV, rhinovirus, and human metapneumovirus.
Table 3 Presence, absence, and mean severity scores of individual ARI symptoms in study participants with RT-PCR
confirmed influenza, stratified by age and influenza vaccination status (n = 324)1
18-49 years 50-64 years ≥65 years
Vaccinated Vaccinated Vaccinated
Symptoms Yes No Yes No Yes No p
(n = 52) (n = 144) (n = 43) (n = 48) (n = 27) (n = 10)
Nasal congestion 2.15 1.95 1.74 1.97 1.89 2.13 0.128
Present (%) 90 89 91 81 70 80 0.465
Absent (%) 10 11 9 19 30 20
Sore throat 2.00 1.97 1.86 1.84 1.67 2.57 0.056
Present (%) 87 76 67 77 56 70 0.112
Absent (%) 13 24 33 23 44 30
Cough 2.39 2.18 2.30 2.47 2.41 2.80 0.046
Present (%) 98 97 100 98 100 100 0.998
Absent (%) 2 3 0 2 0 0
Wheezing 1.88 1.57 1.75 1.68 1.85 1.78 0.607
Present (%) 46 53 65 52 48 90 0.045
Absent (%) 54 47 35 48 52 10
Feverishness 2.17 2.17 1.87 2.11 1.70 2.63 0.016
Present (%) 88 89 91 94 74 80 0.904
Absent (%) 12 11 9 6 26 20
Headache 2.19 2.11 2.03 1.90 1.58 2.13 0.167
Present (%) 83 82 77 88 70 80 0.504
Absent (%) 17 18 23 13 30 20
Muscle aches 2.11 2.24 2.15 2.15 1.93 2.43 0.432
Present (%) 87 88 77 96 56 70 0.163
Absent (%) 13 12 23 4 44 30
Fatigue 2.40 2.34 2.48 2.40 2.25 2.50 0.558
Present (%) 96 94 98 98 89 100 0.955
Absent (%) 4 6 2 2 11 0
1Values for symptom severity scores are reported as mean and p-value, among participants where the symptom was present. Values for the presence/absence of
each symptom are reported as percent of column total, and p-value for chi-square test comparing symptom between each age/vaccination group.
VanWormer et al. BMC Infectious Diseases 2014, 14:231 Page 8 of 10
http://www.biomedcentral.com/1471-2334/14/231
Conclusions
Influenza infection was the strongest predictor of per-
ceived symptom severity among individuals with medic-
ally attended ARI over multiple seasons. There was also
a modest reduction in perceived severity among vacci-
nated vs. unvaccinated individuals ≥65 years old with
confirmed influenza. However, these findings could be
influenced by random effects or measurement biases,
thus further research to confirm this finding in other
populations and seasons is warranted.
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